Meeting
2023 ASCO Annual Meeting
CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER.
Authors
Jessica N. McAlpine
BCCA, Vancouver Cancer Centre, Vancouver, BC, Canada
Jessica N. McAlpine , Kathy Chai-Zung Han , Mary Kinloch , Maroie Barkati , Sarah E. Ferguson , Anthony W. Fyles , Fleur Huang , Iwa Kong , Janice S. Kwon , Helen Mackay , Mark Stafford Carey , Stephen Welch , Tjalling Bosse , Carien L. Creutzberg , Nanda Horeweg , Alexandra Leary , WenLing Liu , Dongsheng Tu , Wendy R. Parulekar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT05640999
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5632)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5632
Abstract #
TPS5632
Poster Bd #
317a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.
First Author: Bradley Corr
Poster
2023 ASCO Annual Meeting
Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.
First Author: Zhen Zeng
Poster
2023 ASCO Annual Meeting
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
First Author: Elizabeth Katherine Lee
First Author: B.J. Rimel